Wechselwirkungen von Paracetamol und Ibuprofen

Hypersensitivity Reactions Serious acute hypersensitivity reactions; including fatal or life-threatening anaphylaxis, rash, hypotension, wheezing, and/or shortness of breath; have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose and occurred soon after initiation of the infusion [ see Adverse Reactions ( 6 ) ]. (Fachinformation zu Acetylcystein, Warnhinweise und Vorsichtsmaßnahmen)

• patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDS [see Warnings and Precautions (5.7 and 5.8) ] . (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

• patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDS [see Warnings and Precautions (5.7 and 5.8) ] . (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Fachinformation zu Apixaban, Boxed Warning (umrahmter Warnhinweis))

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

• patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDS [see Warnings and Precautions (5.7 and 5.8) ] . (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

• patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDS [see Warnings and Precautions (5.7 and 5.8) ] . (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (Fachinformation zu Cidofovir, Arzneimittelwechselwirkungen)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Fachinformation zu Dabigatran, Boxed Warning (umrahmter Warnhinweis))

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Fachinformation zu Edoxaban, Boxed Warning (umrahmter Warnhinweis))

Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (Fachinformation zu Emtricitabin, Rilpivirin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (Fachinformation zu Enoxaparin, Boxed Warning (umrahmter Warnhinweis))

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (Fachinformation zu Fondaparinux, Boxed Warning (umrahmter Warnhinweis))

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (Fachinformation zu Methotrexat, Warnhinweise und Vorsichtsmaßnahmen)

Acetaminophen: Avoid concomitant use with Metopirone. (Fachinformation zu Metyrapon, Arzneimittelwechselwirkungen)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (Fachinformation zu Misoprostol, Boxed Warning (umrahmter Warnhinweis))

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (Fachinformation zu Montelukast, Warnhinweise und Vorsichtsmaßnahmen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

• patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDS [see Warnings and Precautions (5.7 and 5.8) ] . (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (Fachinformation zu Pralatrexat, Arzneimittelwechselwirkungen)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (Fachinformation zu Prasugrel, Boxed Warning (umrahmter Warnhinweis))

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Fachinformation zu Rivaroxaban, Boxed Warning (umrahmter Warnhinweis))

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (Fachinformation zu Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

COMBOGESIC is contraindicated in: • patients with a known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product [see Warnings and Precautions (5.7 , 5.8 , 5.9) ]. (Fachinformation zu Paracetamol und Ibuprofen, Gegenanzeigen)

A baby nursing from an ultra-rapid metabolizer mother taking tramadol hydrochloride and acetaminophen could potentially be exposed to high levels of M1, and experience life-threatening respiratory depression. (Fachinformation zu Tramadol und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (Fachinformation zu Adefovir, Warnhinweise und Vorsichtsmaßnahmen)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Fachinformation zu Afatinib, Warnhinweise und Vorsichtsmaßnahmen)

Premedicate patients with an antihistamine and acetaminophen prior to each dose. (Fachinformation zu Alemtuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (Fachinformation zu Alendronsäure, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Anagrelid, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic Antagonists, or Tricyclic Antidepressants: May produce severe, prolonged… (Fachinformation zu Articain und Adrenalin, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor… (Fachinformation zu Bupivacain und Adrenalin, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (Fachinformation zu Cefotaxim, Arzneimittelwechselwirkungen)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (Fachinformation zu Chloroprocain, Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Cyclosporine Clinical Impact: Concomitant use of NSAIDS and cyclosporine may increase cyclosporine's nephrotoxicity. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (Fachinformation zu Ciprofloxacin, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (Fachinformation zu Dapagliflozin, Arzneimittelwechselwirkungen)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Fachinformation zu Deferasirox, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Fachinformation zu Desmopressin, Arzneimittelwechselwirkungen)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (Fachinformation zu Desogestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Digoxin Clinical Impact: The concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Donepezil, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (Fachinformation zu Drospirenon und Ethinylestradiol, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Fachinformation zu Emtricitabin und Tenofovir, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Fachinformation zu Erlotinib, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. (Fachinformation zu Etonogestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Fachinformation zu Febuxostat, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Similarly, the C max and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Fachinformation zu Galantamin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (Fachinformation zu Ibandronsäure, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Medications for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction [see Dosage and Administration (2.10) and Adverse Reactions (6.1) ] . (Fachinformation zu Infliximab, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Acetaminophen A report of severe acetaminophen toxicity was reported in a patient receiving isoniazid. (Fachinformation zu Isoniazid, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Fachinformation zu Kaliumchlorid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (Fachinformation zu Kaliumcitrat, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (Fachinformation zu Levofloxacin, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Ascorbic acid and acetaminophen may increase systemic exposure of ethinyl estradiol, possibly by inhibition of conjugation. (Fachinformation zu Levonorgestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing epinephrine are… (Fachinformation zu Lidocain und Adrenalin, Arzneimittelwechselwirkungen)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (Fachinformation zu Lidocain und Prilocain, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Lithium Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance . (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (Fachinformation zu Lomitapid, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Memantin und Donepezil, Warnhinweise und Vorsichtsmaßnahmen)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (Fachinformation zu Mepivacain, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (Fachinformation zu Mifepriston, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Premedicate with an analgesic medication (e.g., acetaminophen) prior to each APHEXDA dose. (Fachinformation zu Motixafortid, Warnhinweise und Vorsichtsmaßnahmen)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (Fachinformation zu Moxifloxacin, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Fachinformation zu Nintedanib, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (Fachinformation zu Norelgestromin und Ethinylestradiol, Arzneimittelwechselwirkungen)

Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. (Fachinformation zu Norethisteron und Ethinylestradiol, Arzneimittelwechselwirkungen)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (Fachinformation zu Norgestimat und Ethinylestradiol, Arzneimittelwechselwirkungen)

Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. (Fachinformation zu Norgestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

The addition of an antipyretic (e.g., acetaminophen) may also be considered [see Dosage and Administration (2.2) ]. (Fachinformation zu Ocrelizumab, Warnhinweise und Vorsichtsmaßnahmen)

Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (Fachinformation zu Ofloxacin, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Effects of Other Substances on Acetaminophen Substances that induce or regulate hepatic cytochrome enzyme CYP2E1 may alter the metabolism of acetaminophen and increase its hepatotoxic potential. (Fachinformation zu Paracetamol, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase… (Fachinformation zu Prilocain und Adrenalin, Arzneimittelwechselwirkungen)

In patients on probenecid who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Fachinformation zu Probenecid, Warnhinweise)

In patients on probenecid and colchicine who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (Fachinformation zu Probenecid und Colchicin, Warnhinweise)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Rivastigmin, Warnhinweise und Vorsichtsmaßnahmen)

…Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be used with caution in patients receiving other local anesthetics or agents structurally related to amide- type… (Fachinformation zu Ropivacain, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (Fachinformation zu Tofacitinib, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Fachinformation zu Upadacitinib, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (Fachinformation zu Voriconazol, Arzneimittelwechselwirkungen)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (Fachinformation zu Vortioxetin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. (Fachinformation zu Zaleplon, Arzneimittelwechselwirkungen)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (Fachinformation zu Zenocutuzumab, Warnhinweise und Vorsichtsmaßnahmen)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (Fachinformation zu Zoledronsäure, Arzneimittelwechselwirkungen)

Therapeutic levels of aspirin, desipramine, diazepam, flurazepam, ibuprofen, propranolol, thioridazine, and tolbutamide had only a limited effect on the extent of binding of buspirone to plasma proteins (see CLINICAL PHARMACOLOGY ). (Fachinformation zu Buspiron, Arzneimittelwechselwirkungen)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil,… (Fachinformation zu Carbamazepin, Arzneimittelwechselwirkungen)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (Fachinformation zu Dobutamin, Arzneimittelwechselwirkungen)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (Fachinformation zu Exenatid, Arzneimittelwechselwirkungen)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (Fachinformation zu Finasterid, Arzneimittelwechselwirkungen)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Anaphylaxis and Other Hypersensitivity Reactions Acetaminophen There have been postmarketing reports of hypersensitivity and anaphylaxis associated with the use of acetaminophen. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (Fachinformation zu Pilocarpin, Arzneimittelwechselwirkungen)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (Fachinformation zu Risedronsäure, Arzneimittelwechselwirkungen)

Premedicate patients with an antihistamine and acetaminophen prior to dosing. (Fachinformation zu Rituximab, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (Fachinformation zu Tocilizumab, Arzneimittelwechselwirkungen)

Drugs with No Observed Interactions with REYATAZ No clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, atenolol, or the nucleoside reverse transcriptase inhibitors lamivudine or zidovudine [see Clinical Pharmacology, Tables 21 and 22 (12.3) ] . (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

…Clinically Significant Drug Interaction with TAMIFLU No dose adjustments are needed for either oseltamivir or the concomitant drug when coadministering oseltamivir with amoxicillin, acetaminophen, aspirin, cimetidine, antacids (magnesium and aluminum hydroxides and calcium carbonates), rimantadine, amantadine, or warfarin [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Oseltamivir, Arzneimittelwechselwirkungen)

…included in Table 6, the interaction between EDURANT and the following drugs was evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : acetaminophen, atorvastatin, chlorzoxazone, cabotegravir, ethinylestradiol, norethindrone, raltegravir, sildenafil, simeprevir and tenofovir disoproxil fumarate. (Fachinformation zu Rilpivirin, Arzneimittelwechselwirkungen)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (Fachinformation zu Ropinirol, Arzneimittelwechselwirkungen)

Drugs for which either no interaction or a likely clinically unimportant interaction has been observed Acetaminophen Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients. (Fachinformation zu Valproinsäure, Arzneimittelwechselwirkungen)